Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Kelly, Eimear; Greenland, Melanie; de Whalley, Philip C.S.; Aley, Parvinder K.; Plested, Emma L.; Singh, Nisha; Koleva, Stanislava; Tonner, Sharon; Macaulay, Grace C.; Read, Robert C.; Ramsay, Mary; Cameron, J. Claire; Turner, David P.J.; Heath, Paul T.; Bernatoniene, Jolanta; Connor, Philip; Cathie, Katrina; Faust, Saul N.; Banerjee, Indraneel; Cantrell, Liberty; Mujadidi, Yama F.; Belhadef, Hanane Trari; Clutterbuck, Elizabeth A.; Anslow, Rachel; Valliji, Zara; James, Tim; Hallis, Bassam; Otter, Ashley David; Lambe, Teresa; Nguyen-Van-Tam, Jonathan S.; Minassian, Angela M.; Liu, Xinxue; Snape, Matthew D.; Com-COV3 Study Group, Com-COV3 Study Group

doi:10.1016/j.jinf.2023.06.007

All Outputs (8)

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., Abhishek, A., & . (2024). Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study. Rheumatology, Article keae160. https://doi.org/10.1093/rheumatology/keae160

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients (2024)
Journal Article
Standing, J. F., Buggiotti, L., Guerra-Assunção, J. A., Woodall, M., Ellis, S., Agyeman, A. A., …Breuer, J. (2024). Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nature Communications, 15, Article 1652. https://doi.org/10.1038/s41467-024-45641-0

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care (n... Read More about Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.

Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable (2023)
Journal Article
de Waure, C., Gärtner, B. C., Lopalco, P. L., Puig-Barbera, J., & Nguyen-Van-Tam, J. S. (2024). Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable. Expert Review of Vaccines, 23(1), 27-38. https://doi.org/10.1080/14760584.2023.2290194

INTRODUCTION: Influenza causes significant morbidity and mortality, but influenza vaccine uptake remains below most countries' targets. Vaccine policy recommendations vary, as do procedures for reviewing and appraising the evidence. AREAS COVERED: Du... Read More about Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable.

Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity (2023)
Journal Article
Swets, M. C., Kerr, S., Scott-Brown, J., Brown, A. B., Gupta, R., Millar, J. E., …ISARIC4C Investigators. (2023). Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity. Nature Communications, 14(1), Article 7374. https://doi.org/10.1038/s41467-023-42205-6

Choosing optimal outcome measures maximizes statistical power, accelerates discovery and improves reliability in early-phase trials. We devised and evaluated a modification to a pragmatic measure of oxygenation function, the S/F ratio. Because of the... Read More about Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Study investigators, V. (in press). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology,

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease (2023)
Journal Article
Gbinigie, O., Ogburn, E., Allen, J., Dorward, J., Dobson, M., Madden, T., …Butler, C. C. (2023). Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open, 13(8), Article e069176. https://doi.org/10.1136/bmjopen-2022-069176

Introduction: There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. Met... Read More about Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.

Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study (2023)
Journal Article
Hippisley-Cox, J., Khunti, K., Sheikh, A., Nguyen-Van-Tam, J. S., & Coupland, C. A. (2023). Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. BMJ, 381, Article e072976. https://doi.org/10.1136/bmj-2022-072976

Objectives To derive and validate risk prediction algorithms (QCOVID4) to estimate the risk of covid-19 related death and hospital admission in people with a positive SARS-CoV-2 test result during the period when the omicron variant of the virus was... Read More about Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study.

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial (2023)
Journal Article
Kelly, E., Greenland, M., de Whalley, P. C., Aley, P. K., Plested, E. L., Singh, N., …Com-COV3 Study Group, C. S. G. (2023). Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Journal of Infection, 87(3), 230-241. https://doi.org/10.1016/j.jinf.2023.06.007

Background: This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. Methods: A phase II, single-blind, multi-centre, randomised-controlled trial... Read More about Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.